Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
Public ClinicalTrials.gov record NCT02593227. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Study identification
- NCT ID
- NCT02593227
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Marker Therapeutics, Inc.
- Industry
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Interventions
- Cyclophosphamide Drug
- High dose FRα vaccine Biological
- Low dose FRα vaccine Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2016
- Primary completion
- Jul 14, 2021
- Completion
- Jul 14, 2021
- Last update posted
- Jul 18, 2021
2016 – 2021
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| University of Maryland - Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Karmanos Cancer Center | Detroit | Michigan | 48201 | — |
| MidAmerica Division,Inc | Kansas City | Missouri | 64132 | — |
| The Valley Hospital | Paramus | New Jersey | 07652 | — |
| Mount Sinai Hospital | New York | New York | 10029 | — |
| Montefiore Medical Center, Einstein Cancer Center | New York | New York | 10461 | — |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Texas Oncology Presbyterian Cancer Center Dallas | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02593227, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 18, 2021 · Synced May 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02593227 live on ClinicalTrials.gov.